The blood plasma proteome has a huge potential for the discovery of novel biomarkers that can be applied to assess human health and disease stages. Learn about corner stones of high-throughput proteomics such as lab automation and a robust MS system such as the Bruker timsTOF Pro, which enables the analysis of thousands of plasma samples. We further argue to apply contamination marker panels to evaluate potential biomarker candidates and to analyze large-scale or longitudinal sample sets to deal with biological variation of the proteome. We exemplify the possibility to identify new biomarkers by investigating a longitudinal cohort of COVID-19 patients.
Run time: 14:41 mins
Philipp Geyer, Ph.D. of OmicEra on High-throughput clinical proteomics and applications to COVID-19 Play
Video Credit: Bruker Life Sciences Mass Spectrometry